- About Us
- Phase I
- Phase II
- Data Services
- Core Laboratories
- Media Center
- Contact Us
CRF Health, a global provider of eCOA solutions for the life sciences industry, announces the appointment of Claudine Paccio as the company’s senior vice president, Delivery Services. Paccio will head-up client delivery and development activities at CRF Health, where she will provide leadership, structure and processes to enhance the delivery of the company’s services and […]
Virginia Bio, a statewide nonprofit association representing life science industry in the Commonwealth of Virginia, elected five new members to their board of directors for a term of three years. The election took place in December at the Virginia Bio Annual Membership in Richmond, Virginia. The newly elected members include: Elaine Horn-Ranney, co-founder and CEO […]
Minesh Mehta, M.D., an expert in radiation oncology, proton therapy and cancer research, has joined the executive leadership of Miami Cancer Institute at Baptist Health South Florida as deputy director and chief of radiation oncology. Dr. Mehta will position Miami Cancer Institute’s proton therapy center—the only one of its kind in South Florida and one of fewer […]
The post Miami Cancer Institute names Mehta deputy director, radiology chief appeared first on CenterWatch News Online.
BioClinica, a specialty clinical trials services and technology provider, has acquired Clinverse. The acquisition expands Bioclinica’s offerings into the growing market of automated financial management technology solutions for global clinical trials. Clinverse is the latest investment that Bioclinica has completed to build the company into a leading provider of solutions that bring quality and efficiency […]
Small Business Education Series, a group of Web-based tutorials aimed at educating small pharmaceutical business on topics relating to drug regulation and review.
Alkermes has announced preliminary topline results from FORWARD-3 and FORWARD-4, the first two of three phase III efficacy studies to read out from the comprehensive FORWARD pivotal program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD) in patients who have […]
The post Alkermes has positive phase III results for ALKS 5461 in major depressive disorder appeared first on CenterWatch News Online.